Vertex is hoping for 'historic' non-opioid painkiller approval. It might not be a straightforward blockbuster.
This week, the FDA will decide whether to approve Vertex Pharmaceuticals' non-opioid painkiller. Vertex believes pain could ...
Vertex Pharmaceuticals’ Suzetrigine: A Promising Opioid Alternative in Pain Management
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...
standard-journal1d
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the ...
Is Vertex Pharmaceuticals Stock a Buy in 2025?
The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...
Vertex Pharmaceuticals (VRTX) Receives a Buy from Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's fourth consecutive day of gains.